PMID- 25805886
OWN - NLM
STAT- MEDLINE
DCOM- 20160329
LR  - 20181113
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 41
IP  - 4
DP  - 2015 Jul
TI  - The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and 
      Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized 
      Clinical Trial.
PG  - 859-68
LID - 10.1093/schbul/sbv022 [doi]
AB  - Individuals with schizophrenia display substantial neurocognitive deficits for 
      which available treatments offer only limited benefits. Yet, findings from 
      studies of animals, clinical and nonclinical populations have linked 
      neurocognitive improvements to increases in aerobic fitness (AF) via aerobic 
      exercise training (AE). Such improvements have been attributed to up-regulation 
      of brain-derived neurotrophic factor (BDNF). However, the impact of AE on 
      neurocognition, and the putative role of BDNF, have not been investigated in 
      schizophrenia. Employing a proof-of-concept, single-blind, randomized clinical 
      trial design, 33 individuals with schizophrenia were randomized to receive 
      standard psychiatric treatment (n = 17; "treatment as usual"; TAU) or attend a 
      12-week AE program (n = 16) utilizing active-play video games (Xbox 360 Kinect) 
      and traditional AE equipment. Participants completed assessments of AF (indexed 
      by VO2 peak ml/kg/min), neurocognition (MATRICS Consensus Cognitive Battery), and 
      serum-BDNF before and after and 12-week period. Twenty-six participants (79%) 
      completed the study. At follow-up, the AE participants improved their AF by 18.0% 
      vs a -0.5% decline in the TAU group (P = .002) and improved their neurocognition 
      by 15.1% vs -2.0% decline in the TAU group (P = .031). Hierarchical multiple 
      regression analyses indicated that enhancement in AF and increases in BDNF 
      predicted 25.4% and 14.6% of the neurocognitive improvement variance, 
      respectively. The results indicate AE is effective in enhancing neurocognitive 
      functioning in people with schizophrenia and provide preliminary support for the 
      impact of AE-related BDNF up-regulation on neurocognition in this population. 
      Poor AF represents a modifiable risk factor for neurocognitive dysfunction in 
      schizophrenia for which AE training offer a safe, nonstigmatizing, and 
      side-effect-free intervention.
CI  - (c) The Author 2015. Published by Oxford University Press on behalf of the Maryland 
      Psychiatric Research Center. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Kimhy, David
AU  - Kimhy D
AD  - Department of Psychiatry, Columbia University, New York, NY; New York State 
      Psychiatric Institute, New York, NY; kimhyda@nyspi.columbia.edu.
FAU - Vakhrusheva, Julia
AU  - Vakhrusheva J
AD  - Department of Psychiatry, Columbia University, New York, NY;
FAU - Bartels, Matthew N
AU  - Bartels MN
AD  - Department of Rehabilitation Medicine, Albert Einstein College of Medicine, 
      Bronx, NY;
FAU - Armstrong, Hilary F
AU  - Armstrong HF
AD  - Department of Rehabilitation & Regenerative Medicine, Columbia University, New 
      York, NY;
FAU - Ballon, Jacob S
AU  - Ballon JS
AD  - Department of Psychiatry, Columbia University, New York, NY; New York State 
      Psychiatric Institute, New York, NY;
FAU - Khan, Samira
AU  - Khan S
AD  - New York State Psychiatric Institute, New York, NY;
FAU - Chang, Rachel W
AU  - Chang RW
AD  - New York State Psychiatric Institute, New York, NY;
FAU - Hansen, Marie C
AU  - Hansen MC
AD  - New York State Psychiatric Institute, New York, NY;
FAU - Ayanruoh, Lindsey
AU  - Ayanruoh L
AD  - New York State Psychiatric Institute, New York, NY;
FAU - Lister, Amanda
AU  - Lister A
AD  - New York State Psychiatric Institute, New York, NY;
FAU - Castren, Eero
AU  - Castren E
AD  - Neuroscience Center, University of Helsinki, Helsinki, Finland.
FAU - Smith, Edward E
AU  - Smith EE
AD  - Department of Psychiatry, Columbia University, New York, NY; New York State 
      Psychiatric Institute, New York, NY;
FAU - Sloan, Richard P
AU  - Sloan RP
AD  - Department of Psychiatry, Columbia University, New York, NY; New York State 
      Psychiatric Institute, New York, NY;
LA  - eng
GR  - R21 MH096132/MH/NIMH NIH HHS/United States
GR  - 1R21MH096132/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20150323
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - *Cognition Disorders/blood/etiology/therapy
MH  - Exercise/physiology
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Fitness/physiology
MH  - *Schizophrenia/blood/complications/therapy
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Video Games
PMC - PMC4466187
OTO - NOTNLM
OT  - aerobic fitness
OT  - brain-derived neurotrophic factor/active-play video games
OT  - cognition
OT  - neurotrophins
EDAT- 2015/03/26 06:00
MHDA- 2016/03/30 06:00
PMCR- 2016/07/01
CRDT- 2015/03/26 06:00
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2016/03/30 06:00 [medline]
PHST- 2016/07/01 00:00 [pmc-release]
AID - sbv022 [pii]
AID - 10.1093/schbul/sbv022 [doi]
PST - ppublish
SO  - Schizophr Bull. 2015 Jul;41(4):859-68. doi: 10.1093/schbul/sbv022. Epub 2015 Mar 
      23.